E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Coinfection of Human Immunodeficiency Virus and Herpes Simplex Virus type 2 |
|
E.1.1.1 | Medical condition in easily understood language |
Coinfection of Human Immunodeficiency Virus and Herpes Simplex Virus type 2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare time from baseline until reaching the primary endpoint, either CD4 count of ≤ 350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART (Highly Active Antiretroviral Treatment) for any reason, among adults with both stable untreated HIV and HSV-2 co-infection, between those randomized to valacyclovir compared to those randomized to placebo.
i.e. Among adults co-infected with HIV and HSV-2 who are not using chronic suppressive anti-HSV therapy, and who are neither currently using nor appropriate for initiation of HAART according to current guidelines, can oral valacyclovir 500mg twice daily delay the time until the need for initiating HAART?
|
|
E.2.2 | Secondary objectives of the trial |
-To compare the annual rate of change in the absolute CD4 cell count between study arms. -To compare the annual rate of change in the CD4 cell count percentage between study arms. -To compare the viral load between study arms. -To compare the rate of drug-related adverse events between study arms. -To compare the median frequency of HSV reactivations per year between study arms. -To compare the rate of acyclovir-resistant HSV between study arms. -To compare quality of life between study arms.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-adult (aged 18 years or older or as per Local/Provincial Guidelines) -documented HIV-1 infection (determined by EIA and Western blot) -documented HSV-2 seropositivity (determined by ELISA during screening -no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to require chronic anti-HSV therapy during the study -antiretroviral naïve (no more than 14 days of total prior ARV exposure) -CD4 count within the 400-900 cells/mm3 range (inclusive) on two consecutive occasions, with at least one measurement within 4 weeks of initiating trial (baseline visit) -does not meet recommendations for initiating ARV therapy according to current guidelines
|
|
E.4 | Principal exclusion criteria |
-pregnancy or actively planning to become pregnant -receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.) -Estimated creatinine clearance <30 mL/min -Other medical condition likely to cause death within 24 months -Enrolled in a therapeutic HIV vaccine or immunotherapy trial -Enrolled in another trial investigating the impact of another intervention on HIV disease progression -HIV elite controller (EC), phenotypically defined here as documented duration of HIV infection of ≥5 years, a persistent CD4 cell count ≥500 cells/mm3, and a persistent plasma HIV viral load of <1000 copies/mL in the absence of antiretroviral therapy
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is the time from baseline until reaching the primary endpoint, a composite of either a CD4 cell count ≤350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first. This endpoint was selected because reaching the treatment threshold for initiating HAART is an important clinical event signifying the need for lifelong therapy. The CD4 count of ≤350 cells/mm3 must be confirmed by a second measurement to verify the CD4 count is within the treatment range before initiating therapy. The primary endpoint also includes the initiation of HAART for any reason, since patients who start HAART outside these guidelines are also committed to lifelong therapy. This group may include individuals who choose to start therapy at earlier stages of disease (e.g. due to high viral load set-point), and some who develop HIV-related complications (e.g. tuberculosis) at higher CD4 cell counts, among others. For example, women who initiate HAART during pregnancy primarily for the prevention of mother-to-child transmission of HIV, and hepatitis B co-infected individuals who initiate HAART primarily for the purposes of treating their hepatitis B infection will also be considered to have met the primary endpoint. It was important not to restrict the primary endpoint to initiation of HAART alone, since some patients may not initiate HAART despite reaching treatment thresholds for reasons including patient anxiety, concerns about adherence, and lack of familiarity with guidelines.
HAART initiation guidelines are continuously under evaluation, and it is recognized that there is a possibility that HIV treatment guidelines may change. However, this concern will not threaten the integrity of the study because the primary endpoint of this study is a composite of not only meeting the current CD4 threshold of 350 cells/mm3, but also the initiation of HAART for any reason, whichever occurs first. Finally, randomization in this trial will be stratified by site to help account for any variation in practice regarding initiation of HAART across sites.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline to either a CD4 cell count ≤350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason (whichever occurs first). |
|
E.5.2 | Secondary end point(s) |
To compare the annual rate of change in the absolute CD4 cell count between study arms. To compare the annual rate of change in the CD4 cell count percentage between study arms. To compare the median log10 HIV viral load between study arms. To compare the rate of drug-related adverse events between study arms. To compare the median frequency of HSV reactivations year between study arms. To compare the rate of acyclovir-resistant HSV between study arms. To compare quality of life between study arms. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From baseline to end of study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 29 |